MedPath

安徽海斯美医药有限公司

Ownership
-
Established
2021-08-20
Employees
-
Market Cap
-
Website

Clinical Trials

0

Active:0
Completed:0

Trial Phases

0 Phases

Drug Approvals

6

NMPA:6

Drug Approvals

Ambroxol Hydrochloride Oral Solution

Product Name
盐酸氨溴索口服溶液
Approval Number
国药准字H20254360
Approval Date
May 27, 2025
NMPA

Ambroxol Hydrochloride Oral Solution

Product Name
盐酸氨溴索口服溶液
Approval Number
国药准字H20249794
Approval Date
Dec 25, 2024
NMPA

Sodium Valproate Oral Solution

Product Name
丙戊酸钠口服溶液
Approval Number
国药准字H20249518
Approval Date
Dec 1, 2024
NMPA

Urapidil Hydrochloride Injection

Product Name
盐酸乌拉地尔注射液
Approval Number
国药准字H20249145
Approval Date
Oct 22, 2024
NMPA

Urapidil Hydrochloride Injection

Product Name
盐酸乌拉地尔注射液
Approval Number
国药准字H20249146
Approval Date
Oct 22, 2024
NMPA

Aminocaproic Acid Injection

Product Name
氨基己酸注射液
Approval Number
国药准字H20243608
Approval Date
Apr 24, 2024
NMPA

Clinical Trials

No trials found

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.